PSMA PET Parameters for Predicting Outcomes in Patients with Prostate Cancer

HomeRadiologyVol. 309, No. 3 PreviousNext Reviews and CommentaryEditorialPSMA PET Parameters for Predicting Outcomes in Patients with Prostate CancerA. Cahid Civelek A. Cahid Civelek Author AffiliationsFrom the Department of Radiology, Division of Nuclear Medicine, Johns Hopkins Medical Institutions, 601 N Caroline St, JHOC 3225, Baltimore, MD 21287.Address correspondence to the author (email: [email protected]).A. Cahid Civelek Published Online:Dec 5 2023https://doi.org/10.1148/radiol.233023MoreSectionsFull textPDF ToolsAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookXLinked In References1. Civelek AC. Reawakening of Nuclear Medicine through Molecular Imaging: Quantitative Theranostics and PSMA PET. Radiology 2023;307(4):e230627. Link, Google Scholar2. Civelek AC, Niglio SA, Malayeri AA, et al. Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol 2021;39(11):787.e17–787.e21. Crossref, Medline, Google Scholar3. van Leeuwen PJ, Emmett L, Ho B, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017;119(2):209–215. Crossref, Medline, Google Scholar4. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017;71(4):630–642. Crossref, Medline, Google Scholar5. Murad V, Glicksman RM, Berlin A, Santiago A, Ramotar M, Metser U. Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer. Radiology 2023;309(3):e231407. Link, Google Scholar6. Gafita A, Djaileb L, Rauscher I, et al. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology 2023;308(1):e222148. Link, Google ScholarArticle HistoryReceived: Nov 6 2023Revision requested: Nov 7 2023Revision received: Nov 9 2023Accepted: Nov 13 2023Published online: Dec 05 2023 FiguresReferencesRelatedDetailsRecommended Articles Reawakening of Nuclear Medicine through Molecular Imaging: Quantitative Theranostics and PSMA PETRadiology2023Volume: 307Issue: 4Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate CancerRadiology2023Volume: 309Issue: 3Invited Commentary: Prostate-specific Membrane Antigen PET Response Assessment—Has the Time Come?RadioGraphics2020Volume: 40Issue: 5pp. 1431-1433Competitive Advantage of PSMA Theranostics in Prostate CancerRadiology2021Volume: 299Issue: 2pp. 261-263177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate CancerRadiology2022Volume: 306Issue: 2See More RSNA Education Exhibits Towards Structured PET Reporting with PSMA Tracers in Prostate CancerDigital Posters2022Assessment of Response to Androgen Deprivation Therapy in Patients With Metastatic Castration-Resistant or Hormone-Sensitive Prostate Cancer by Radiolabeled Choline PET/CT: A Pictorial EssayDigital Posters2022Patterns of Prostate Cancer Response to Systemic Therapy on 68Ga-PSMA PET/CTDigital Posters2020 RSNA Case Collection Hydrogel infiltration into rectal wallRSNA Case Collection2020Radioembolization of Liver Metastasis RSNA Case Collection2020Parasagittal meningiomaRSNA Case Collection2022 Vol. 309, No. 3 Metrics Altmetric Score PDF download